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REVIEW
Abstract: Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor 
sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. 
It is highly protein bound with a small volume of distribution and a nine-hour half-life. Cande-
sartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE 
was searched using OVID and PubMed to evaluate the evidence for using candesartan in patients 
with heart failure. Pharmacologic and pharmacokinetic evaluations, as well as clinical trials, 
were selected and are presented in this review. Clinical evidence supports the indication for use 
in systolic heart failure. Results for use in patients with diastolic heart failure were non-signiﬁ  -
cant. Candesartan was well tolerated in the trials, with hyperkalemia, renal dysfunction, and 
hypotension being the most common adverse events. Use of angiotensin receptor blockers with 
angiotensin-converting enzyme inhibitors needs further study; however, candesartan appears to 
provide added beneﬁ  t in this setting. Candesartan is a safe and effective option for patients with 
systolic heart failure. Data regarding other angiotensin receptor blockers is underway. 
Keywords: candesartan, heart failure, angiotensin receptor blocker
Introduction
Chronic heart failure (HF) affects approximately 5 million people in the US, and affects 
men and women almost equally (AHA 2006). Improvements in the management of 
cardiovascular disease with medications and procedures prolong the lives of patients, 
leading to a larger elderly population with structural heart abnormalities. The burden 
of HF is increasing, as it is often a consequence of other forms of cardiovascular 
disease. It is estimated that by 2037 the prevalence of HF will double (Rich 1997). 
The ﬁ  nancial burden is on the rise as well; direct and indirect costs of HF for 2006 
are estimated to be US$29.6 billion in the US (AHA 2006). In spite of the progress 
and cost, however, HF mortality remains high, with up to 20% of patients dying each 
year (AHA 2006).
Management of HF has evolved substantially in the last two decades. Trials 
showing the beneﬁ  ts of angiotensin-converting enzyme inhibitors (ACE-I) in HF 
established ACE-I as a standard of care (Adams et al 2006), reducing overall deaths 
by approximately 20% (Flather et al 2000). In the early 1990s, the Metoprolol in 
Dilated Cardiomyopathy trial showed β-blockers may have beneﬁ  cial rather than 
detrimental effects in patients with left ventricular (LV) systolic dysfunction who were 
already on established ACE-I therapy (Waagstein et al 1993); this was conﬁ  rmed by 
studies showing reduced mortality with carvedilol and metoprolol succinate (Packer 
et al 1996; Merit-HF 1999; Adams et al 2006). Aldosterone antagonists (spironolac-
tone and eplerenone) also prolong life in patients with advanced HF (Pitt et al 1999, 
2003). Evaluation of angiotensin receptor blockers (ARBs) in HF has recently been 
conducted to address the continued high mortality rates in spite of the treatment ad-
vances (Cohn et al 2001; CHARM Program 2003; Pfeffer et al 2003). Additionally, 
approximately 20% of patients with LV dysfunction are not treated with ACE-I, 
usually because of intolerance (Bart et al 1999). Other common therapies used in HF 
are diuretics and digoxin for symptomatic management. Clearly, the magnitude of 
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pharmacotherapy for chronic HF has expanded. Ascertaining 
appropriate evidence-based use of ARBs in HF, a possible 
addition to an already copious drug regimen, is critical to 
minimize risk and maximize therapeutic beneﬁ  t. Within the 
class of ARBs, only two agents are approved for HF in the 
US: valsartan (Diovan
®, Novartis Pharmaceuticals, NJ, USA) 
and candesartan (Atacand
®, AstraZeneca, DE, USA). 
Pathophysiology 
Heart failure is not a single entity, but a cycle of damage 
and neurohormonal activation that begins with an adverse 
cardiovascular environment, causing or leading to cardiac in-
jury. The initial damage can be caused by various conditions, 
including ischemia, uncontrolled hypertension, and autoim-
mune myocarditis (Willerson 1995). The cycle culminates 
with systolic or diastolic dysfunction that decreases cardiac 
output and compromises organ perfusion. A compensatory 
response to improve organ perfusion begins with renin release 
and renin–angiotensin–aldosterone system (RAAS) activa-
tion. Renin is primarily released by juxtaglomerular cells of 
the kidneys; it catalyzes the conversion of angiotensinogen 
to angiotensin which is then converted to angiotensin II by 
the ACE (Delgado and Willerson 1999). 
Angiotensin II stimulates additional compensatory re-
sponses. By activating angiotensin type 1 (AT1) receptors, 
angiotensin II increases blood pressure by multiple mecha-
nisms (Dostal 2000). First, it causes a rapid pressor response 
by direct vasoconstriction. Angiotensin II also activates the 
sympathetic nervous system, increases endothelin and va-
sopressin secretion, and increases peripheral noradrenergic 
transmission (Farrell et al 2001). Constriction of the efferent 
renal arterioles increases glomerular ﬁ  ltration and peritubu-
lar oncotic pressure, promoting reabsorption of sodium and 
water in the proximal tubule. This compensatory response 
is protective initially, but chronically elevated angiotensin 
II can cause vascular and cardiac hypertrophy, vascular and 
cardiac ﬁ  brosis, and induction of cardiac arrhythmias (Kim 
and Iwao 2000). 
Furthermore, angiotensin II stimulates the adrenal gland 
to release aldosterone. Aldosterone binds to mineralocorti-
coid receptors to promote sodium reabsorption, potassium ex-
cretion, and passive water retention. Fluid retention increases 
stress on the heart, further stimulating the hormonal activa-
tion and myocardial remodeling. Additionally, aldosterone 
synthetase is found in extraadrenal tissues such as the heart, 
blood vessels, and brain, resulting in aldosterone release via 
non-angiotensin II pathways (Weber 2001).
In addition to sympathetic activation, cardiac injury also 
leads to remodeling of the myocardium. Acute injury, such 
as myocardial infarction, causes a decrease in pressure of 
the baroreceptors in the aortic arch, causing sympathetic 
nervous system stimulation. The sympathetic hormones 
(norepinephrine, vasopressin, and atrial naturetic peptide) 
increase heart rate, afterload, and cause myocardial remod-
eling (Jesseup and Brozena 2003). Norepinephrine also 
predisposes to ventricular arrhythmias and cardiac arrest. 
Myocardial remodeling worsens cardiac output, augment-
ing the cycle of RAAS activation and cardiac remodeling 
(Delgado and Willerson 1999). 
The interrelated hormonal activation and subsequent 
cardiac toxicity make identifying the appropriate targets 
to stop this cycle critical. Blocking both the receptors and 
the production of angiotensin II has been shown to stop the 
progression of HF and is an important component of HF 
therapeutics (Pitt et al 1997). Prior to development of these 
neurohormonal interventions, HF mortality was greater than 
50% at 5 years (Aghababian 2002). By adequately block-
ing ACE, mortality can be reduced by approximately 30% 
(Garg and Yusuf 1995) in spite of incomplete blockade of 
angiotensin II production. Blocking the angiotensin receptor 
sub-type 1 (AR1) receptor as an alternative or in addition to 
ACE inhibition is a reasonable target to attempt to slow the 
consequences of neurohormonal activation in HF. 
Pharmacology
Blockade of angiotensin II production via ACE inhibition 
does not lead to complete blockade of the RAAS (Francis 
et al 2004). In fact, angiotensin II returns to pre-treatment 
levels in spite of chronic treatment with ACE-I (Biollaz et al 
1982; Urata, et al 1990; Jorde et al 2000). This is due, in 
part, to angiotensin II generation through non-ACE depend-
ent pathways which include enzymes such as cathepsin G, 
elastase, tissue plasminogen activator and chymase (Volpe 
et al 2003).
Angiotensin II targets two major receptor subtypes, AT1 
and AT2. The AT1 receptor is well characterized. Activation 
of the AT1 receptor leads to marked vasoconstriction, 
norepinephrine release, sensitization of blood vessels to nore-
pinephrine, sympathetic activation, aldosterone secretion and 
vascular hypertrophy (Francis et al 2004). Although less well 
deﬁ  ned, it has been suggested that AT2 activation counteracts 
the effects of AT1 through vasodilatory and antigrowth ef-
fects (Volpe et al 2003). Moreover, AT1 receptor blockade 
leads to increased circulating levels of angiotensin II avail-
able to exert these proposed beneﬁ  cial actions unopposingly 
on AT2 receptors. However, accumulating evidence has Clinical Interventions in Aging 2006:1(4) 359
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challenged this counter-regulatory role of AT2. Animal 
models demonstrated that AT2 receptors may have cardiac 
hypertrophic and proliferative actions, while other reports 
suggest AT2 receptors demonstrate neutral effects on 
cardiac structure and function (Widdop et al 2003; Lévy 
2004; d’Amore et al 2005). These observations suggest AT1 
blockade could be beneﬁ  cial in patients with HF; however, 
the effect of unopposed AT2 stimulation is still unclear.
Candesartan is a nonpeptide angiotensin II receptor 
antagonist that selectively inhibits the binding of angi-
otensin II to the AT1 receptor. In animal models, candesartan 
demonstrates insurmountable receptor antagonism with high 
afﬁ  nity for and slow dissociation from the AT1 receptor 
(Easthope and Jarvis 2002). AT1 receptor binding afﬁ  nity 
for candesartan was approximately 80 and 100 times greater 
compared with losartan potassium and its active metabolite 
(E3174), respectively (Nishikawa et al 1997).
Pharmacokinetics
Candesartan cilexetil is administered orally as a prodrug and then 
rapidly and completely converted to its active form candesartan 
via ester hydrolysis during gastrointestinal absorption. Its 
pharmacokinetic properties have been evaluated in healthy 
volunteers. Absolute oral bioavailability of candesartan 
cilexetil is variable and has been cited as approximately 15% 
(Easthope and Jarvis 2002) and as 42% (van Lier et al 1997). 
Absorption of candesartan is not signiﬁ  cantly inﬂ  uenced by 
food (Riddell 1997). It is highly protein bound (>99%) with a 
relatively low volume of distribution (0.13 L/kg) and reaches 
peak concentrations in approximately 3–5 hours (tmax) (Easthope 
and Jarvis 2002). In a pharmacokinetic study of healthy 
volunteers, single and repeated administration of candesartan 
demonstrated similar dose-related results for area under the 
plasma concentration–time curve (AUC) and maximum serum 
concentration (Cmax), consistent with no accumulation of the 
drug at steady state (Hübner et al 1997). Almost all of cande-
sartan is eliminated in the urine and feces (99%), with 70%–80% 
as unchanged drug and 20%–30% metabolized to an inactive 
metabolite (van Lier et al 1997; Easthope and Jarvis 2002). 
Metabolism occurs via the cytochrome P450 isoenzyme 2C9, 
with a smaller contribution by de-ethylation and glucuronidation 
(van Lier et al 1997; Easthope and Jarvis 2002). Candesartan’s 
half-life is nine hours; it is minimally removed by dialysis 
(Easthope and Jarvis 2002). 
Clinical trials review
Candesartan was approved for use in HF by the US Food and 
Drug Administration (FDA) in February 2005 (FDA 2006b) 
and was approved in Europe in 2004. Evidence to support 
use in HF stems mainly from the Candesartan in Heart 
Failure Assessment of Reduction in Mortality and morbid-
ity (CHARM) programs, although other smaller trials have 
evaluated candesartan in HF as well (Table 1).
Trials evaluating candesartan’s effects on surrogate end-
points in HF provided a foundation for large scale outcome 
studies. In the Randomized Evaluation of Strategies for Left 
Ventricular Dysfunction (RESOLVD) Pilot study (McKelvie 
et al 1999), 768 patients were randomly assigned to enalapril, 
candesartan, or enalapril plus candesartan over 43 weeks. 
Patients with New York Heart Association functional class 
(NYHA-FC) II–IV, 6-minute walk distance (6MWD) <500 
meters, and ejection fraction (EF) <40% were randomized. 
Although there were no changes in NYHA-FC, quality of 
life (QOL), 6MWD or EF among the groups, there were 
differences among the groups in both end diastolic volume 
(EDV) and end systolic volume (ESV) over time compared 
with baseline values (p=0.007 and p=0.006, respectively) 
with candesartan and enalapril showing increases. The reduc-
tion in ESV suggests possible prevention of LV dilatation 
with the combination. Neurohormone levels were generally 
similar throughout the groups with a few exceptions. There 
were no signiﬁ  cant differences in creatinine or patients with 
hyperkalemia, although potassium levels were higher in the 
combination group (p<0.05). Blood pressure declined more 
with the combination (p<0.01). No signiﬁ  cant differences 
were found in mortality and hospitalizations among the 
groups. Mitrovic and colleagues (2003) also found com-
parable results when evaluating candesartan’s effects on 
similar surrogate endpoints. These ﬁ  ndings suggested that 
candesartan may be safe and effective alone or in combina-
tion with an ACE-inhibitor in patients with HF. 
Granger and colleagues (2000) randomly assigned 270 
patients with HF and a history of ACE-I intolerance to receive 
either candesartan 4 mg, 8 mg, or 16 mg versus placebo for 
12 weeks, with a primary endpoint of tolerability (deﬁ  ned 
as percentage of patients completing the treatment period) 
(Granger et al 2000). The most common reasons for ACE-I 
intolerance were cough (67%), hypotension (15%), and renal 
dysfunction (11%). No signiﬁ  cant differences were found 
in discontinuation rates between the groups (candesartan 
17.3% vs placebo 13.2%; no p-value reported). Symptomatic 
hypotension was more common with candesartan (p=0.03; 
candesartan 18.4% vs placebo 11.0%). No differences were 
found in major cardiovascular events (death, worsening HF, 
hospitalizations, myocardial infarction, stroke), NYHA-FC, 
QOL as assessed by the Minnesota Living with Heart Failure Clinical Interventions in Aging 2006:1(4) 360
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Questionnaire or SF-36 Health Survey, or the 6MWD. Blood 
pressure was reduced with candesartan (10/6 mmHg) with 
no changes in heart rate. Creatinine levels increased more 
than 1.1 mg/dL in 1.1% of candesartan patients; 2.2% of 
candesartan and placebo patients experienced hyperkalemia 
(potassium >5.5 mg/dL). These results also suggested that 
candesartan may be a safe and effective alternative for 
patients intolerant of ACE-inhibitors.
Table 1 Summary of clinical trials evaluating candesartan in heart failure
Trial   N   EF   Design   Intervention/  Primary    Statistical 
       evaluation   endpoints   result 
RESOLVD   768   <40%    PR, MC, R, DB, PC   Cand  4 mg, 8 mg, or 16 mg QD   Change in 6MWD;   NS 
       alone  vs   EF;   NS 
       Cand  4 mg or 8 mg QD + Enal   Ventricular volumes;    p<0.05,  0.01
a 
       10 mg bid vs Enal 10 mg bid alone     Neurohormone levels;    p<0.05,  0.01
b 
         QOL;   NS 
 `        NYHA-FC   NS 
SPICE   270   <35%    PR, R,   Cand 4 mg QD (start) up   Discontinuation rates   NS   
      DB, PC,   to 16 mg 
     pilot    QD (goal) vs placebo in patients 
        intolerant of ACE-I    
CHARM-Added   2548   <40%    PR, R,   Cand 4 mg QD (start) up to  CV death or unplanned   HR 0.85, 0.75–
      DB, PC, P   16 mg   heart failure   0.96, p=0.011 
        QD (goal) vs placebo in addition   hospital admission 
        to established ACE-I therapy    
CHARM-Alternative   2028   <40%    PR, R, DB, PC, P   Cand  4 mg QD (start) up to   CV death or unplanned   HR 0.77, 0.67–0.89, 
       16 mg QD (goal) vs placebo as   heart failure hospital   p=0.0004 
        alternative to ACE-I therapy   admission   
CHARM-Preserved   3023   >40%    PR, R, DB, PC, P   Cand  4 mg QD (start) up to   CV death or unplanned   HR 0.89, 0.77–1.03, 
       16 mg QD (goal) vs placebo   heart failure hospital   p=0.118 
        +/- ACE-I therapy
c   admission   
CHARM-Overall   7599    ——  PR, R, DB, PC, P    Intervention per individual   All-cause death    HR 0.91, 0.83–1.00, 
       CHARM  protocol     p=0.055;   Adjusted 
            HR 0.90 (0.82–
           0.99),  p=0.032 
Cause-speciﬁ  c   1831   ——    Post-hoc CHARM   Compare cause of mortality   Sudden death      HR 0.85, 0.73–0.99, 
 
mortality – CHARM   deaths      data    between candesartan and     p=0.036
 to        placebo    Death from   HR 0.78, 0.65–
 evaluate         progressive HF   0.94,  p=0.008 
NYHA-FC – CHARM   7587   ——    Post-hoc CHARM   Compare % improved and %   Last visit carried   p=0.003
e 
     data    deteriorated between   forward
d   
        candesartan and placebo    Worst rank carried     p=0.003
e 
         forward
d   
Adherence – CHARM   7412
f   ——    Post-hoc CHARM   Compare outcomes in patients   Rate of adherence          89% good    
     data    with good adherence (deﬁ  ned as     adherence; 11% 
        adherent 80% of the time)      poor adherence  
          Mortality overall   HR 0.66, 0.58–0.76,
          (good vs poor   p<0.0001 
         adherence)   
         Candesartan       HR 0.70, 0.57–
           0.86,  p<0.0001 
         Placebo      HR 0.62, 0.51–
           0.76,  p<0.001 
Notes: 
aLevel of signiﬁ  cance depends of parameter measured and intervention compared (refer to full text for detail); 
bRefer to full text for detail; variations in which 
neurohormones reached signiﬁ  cance exists; 
cACE-I were allowed after results of Heart Outcomes Prevention Evaluation were presented; 
dTwo methods were used to 
assess change in NYHA-FC (refer to full text for description); 
eIn favor of candesartan; 
f187 patients were excluded because of missing data; rates of missing data similar 
between treatment groups. 
Abbreviations: ACE-I, Angiotensin-converting enzyme inhibitor; bid, twice daily; Cand, candesartan; CHARM, Candesartan in Heart Failure Assessment of Reduction in 
Mortality and morbidity; DB, double-blind; EF, ejection fraction; Enal, enalapril; HR, Hazard Ratio; MC, multi-centered; NS, not signiﬁ  cant; NYHA-FC, New York Heart 
Association Functional Class; P, parallel; PC, placebo-controlled; PR, prospective; QD, once daily; QOL, quality of life; R, randomized; RESOLVD, Randomized Evaluation of 
Strategies for Left Ventricular Dysfunction; SPICE, Study of Patients Intolerant of Converting Enzyme Inhibitors; 6MWD, 6 minute walk distance. Clinical Interventions in Aging 2006:1(4) 361
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In the largest trial to date, candesartan was evaluated 
in Candesartan in Heart Failure Assessment of Reduction 
in Mortality and morbidity programs (CHARM-Added 
2003; CHARM-Alternative 2003; CHARM-Overall 
2003; CHARM-Preserved 2003). Overall, 7599 patients 
with chronic HF were assigned to one of three protocols: 
CHARM-Alternative, for patients with ACE-I intolerance; 
CHARM-Added, for patients established on ACE-I therapy; 
and CHARM-Preserved, for patients with isolated diastolic 
dysfunction. The primary outcome for the overall analysis 
was all-cause death, while each individual protocol’s pri-
mary outcome was occurrence of cardiovascular death or 
unplanned hospital admission for HF (see Figure 1). The 
trial was powered towards the overall analysis: there was 
an 85% power to detect a 14% reduction in mortality at 
a signiﬁ  cance level of 0.05. Patients were followed for a 
median duration of 37.7 months. At six months, the average 
dose in the candesartan and placebo group was 24 mg and 
27 mg, respectively. 
In the CHARM-Alternative protocol, 2028 patients 
intolerant of ACE-I were randomized to candesartan or 
placebo and were followed for 33.7 months. The most com-
mon reasons for ACE-I intolerance included cough (72%), 
hypotension (13%), and renal dysfunction (12%). There 
was a 23% relative risk reduction (RRR) in the primary 
endpoint (p=0.0004; placebo 40% vs candesartan 33%). 
There was no difference in the number of hospitalizations 
between the groups (p=0.06, placebo 1835 admissions 
vs candesartan 1718 admissions). More patients taking 
candesartan experienced a myocardial infarction compared 
to placebo (p=0.025; placebo 4.7% vs candesartan 7.4%), but 
there were no differences between the groups for stroke or 
coronary revascularization (p=0.42 and p=0.79, respectively). 
By study end, 24% of the candesartan group and 22% of the 
placebo group had permanently discontinued study medica-
tion (p=0.49). Angioedema occurred in three patients taking 
candesartan, all of whom were considered ACE-I intolerant 
because of angioedema on ACE-I. No cases were deemed 
life-threatening or lead to hospitalizations; in two cases, 
candesartan was resumed without recurrence.
In the CHARM-Added protocol, 2548 patients already re-
ceiving an ACE-I were randomized to candesartan or placebo 
and were followed for 41 months. There was a 15% RRR in 
the primary outcome (p=0.011; placebo 42% vs candesartan 
38%). Similarly, there was a 16% RRR in cardiovascular 
death (p=0.029; placebo 27% vs candesartan 24%) and a 
17% RRR in HF hospitalizations (p=0.014; placebo 28% 
vs candesartan 24%). There were fewer all-cause hospital 
admissions in the candesartan group (p=0.023; placebo 2798 
admissions vs candesartan 2462 admissions). Fewer patients 
experienced a myocardial infarction with candesartan com-
pared with placebo (p=0.012, placebo 5.4% vs candesartan 
3.4%). There was no signiﬁ  cant difference in all-cause death 
(p=0.086; placebo 32% vs candesartan 30%). Importantly, 
patients taking β-blockers, ACE-I, and candesartan did not 
have higher mortality than patients taking an ACE-I plus 
candesartan (p=0.20, placebo 39% and candesartan 35%). 
In a previous trial, a sub-analysis demonstrated that patients 
CHARM-Overall; N=7599 
Primary outcome: all-cause death 
CHARM-Alternative; N=2028 
Primary outcome: occurrence of 
cardiovascular death or unplanned 
hospital admission for heart failure 
CHARM-Added; N=2548 
Primary outcome: occurrence of 
cardiovascular death or unplanned 
hospital admission for heart failure 
CHARM-Preserved; N=3023 
Primary outcome: occurrence of 
cardiovascular death or unplanned 
hospital admission for heart failure 
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taking β-blocker, ACE-I and valsartan had worse outcomes 
(Cohn et al 2001). Although two large clinical trials have not 
conﬁ  rmed this ﬁ  nding (CHARM-Added 2003; CHARM-Al-
ternative 2003; CHARM-Overall 2003; CHARM-Preserved 
2003; Pfeffer et al 2003), expert guidelines provide inconsist-
ent recommendations regarding use of triple therapy (HFSA 
2006; ACC–AHA 2005). 
In the CHARM-Preserved protocol, 3023 patients with 
isolated diastolic dysfunction were randomized candesartan 
or placebo and were followed for 36.6 months. There was 
no difference in the primary outcome between the treatment 
groups (p=0.118, unadjusted; p=0.051, adjusted; placebo 
24% vs candesartan 22%). HF hospital admissions were low-
er for the candesartan group than placebo (p=0.014; placebo 
566 admissions vs candesartan 402 admissions). However, 
there was no difference in all-cause hospitalizations. Patients 
taking candesartan were less likely to be diagnosed with 
diabetes (p=0.005; placebo 77 vs candesartan 47).
In the CHARM-Overall analysis, there was a 9% RRR 
in all-cause mortality that did not reach statistical signiﬁ  -
cance initially (p=0.055; placebo 25% vs candesartan 23%), 
but became significant after adjustments for covariates 
(p=0.032; hazard ratio [HR] 0.9, 95% conﬁ  dence interval 
[CI] 0.82–0.99). The lower mortality was largely attributed 
to fewer cardiovascular deaths (p=0.012; placebo 20% vs 
candesartan 18%). However, there were more deaths due 
to cancer in patients taking candesartan (p=0.038; placebo 
1.6% vs candesartan 2.3%). Time to cardiovascular death or 
hospital admission for HF was reduced by 16% (p<0.0001; 
placebo 35% vs candesartan 30%). Although there were some 
differences in frequency of myocardial infarction within the 
individual protocols, there were no signiﬁ  cant differences 
overall for incidence of myocardial infarction, stroke, or 
coronary revascularization. Fewer patients taking cande-
sartan were hospitalized for any reason (p=0.015; placebo 
7178 admissions vs candesartan 6690 admissions). In patients 
without a diagnosis of diabetes prior to the study, patients 
taking candesartan were less likely to develop diabetes during 
the trial (p=0.02; placebo 7% vs candesartan 6%). Treatment 
effect did not differ based on sex, age, EF, NYHA-FC, dia-
betes, or concomitant medications. More patients stopped 
taking candesartan than placebo due to hypotension, elevated 
serum creatinine, and hyperkalemia (p<0.0001 for all adverse 
effects; placebo 16.7% vs candesartan 21.0%).
A post-hoc evaluation of candesartan’s effect on cause-
speciﬁ  c mortality in the CHARM-Overall program was 
performed (Solomon et al 2004). The analysis demonstrated 
signiﬁ  cant reductions in sudden death (HR 0.85, 0.73–0.99, 
p=0.036) and progressive HF (HR 0.78, 0.65–0.94, p=0.008), 
the two most common causes of death in patients with HF. 
Notably, however, there did not appear to be a difference in 
these causes of death in the patients speciﬁ  cally enrolled in 
the CHARM-Preserved protocol. Frequency of other com-
mon causes of death, such as stroke, myocardial infarction, 
and procedure-related mortality were similar to placebo.
The effect of candesartan on NYHA-FC was evaluated 
using the CHARM-Overall data (O’Meara et al 2004). In 
the CHARM trial, NYHA-FC was assessed every two 
weeks during titration, then every four months thereafter. 
The investigators used two analyses to evaluate effect. The 
ﬁ  rst was “last visit carried forward”, which carried forward 
the last available NYHA-FC documented when follow up 
data was not available due to study withdrawal or death. The 
second analysis was the “worst rank carried forward”, which 
assigned patients who died a NYHA-FC of V. For both ap-
proaches, candesartan showed more improvement and less 
deterioration in NYHA-FC (p=0.003 for last visit carried 
forward; p=0.003 for worst rank carried forward).
Granger and colleagues used the CHARM-Overall data to 
evaluate the effect of adherence to study medication on clini-
cal outcomes (Granger et al 2005). The proportion of study 
pills taken was assessed at each follow-up visit throughout 
the CHARM trial. The investigators deﬁ  ned good adherence 
as being adherent at least 80% of the time and poor adher-
ence as being adherent less than 80% of the time; 89% of 
patients were at least 80% adherent, while 11% were less than 
80% adherent. Good adherence was associated with lower 
all-cause mortality overall (HR 0.66, 95% CI 0.58–0.76, 
p<0.0001), as well as in each treatment group (candesartan 
HR 0.70, 0.57–0.86, p<0.001; placebo HR 0.62, 0.51–0.76, 
p<0.001).
Safety proﬁ  le
Several trials have reported the safety of candesartan in HF. 
The RESOLVD trial found higher serum potassium when 
candesartan was used in combination with enalapril. Other 
expected side effects (hypotension, serum creatinine eleva-
tion) were similar to enalapril. 
In the CHARM trial, patients treated with candesartan 
were more likely to experience serum creatinine elevations 
after six weeks (p<0.0001), a doubled serum creatinine 
(p=0.002), hyperkalemia (p=0.017), and lowered blood 
pressure (systolic blood pressure decreased by 5.2 mmHg, 
diastolic blood pressure decreased by 3.0 mmHg versus no 
change in placebo, p<0.001). By the end of the study, 23% 
of candesartan patients and 19% of placebo patients had Clinical Interventions in Aging 2006:1(4) 363
Candesartan in heart failure
permanently discontinued study medication (p=0.0001). 
Patients stopped the medication due to hypotension, increase 
in serum creatinine, or hyperkalemia (p<0.0001 for all caus-
es). Angioedema occurred more in the candesartan patients 
(0.13% vs 0.08%), but no statistical data was reported. 
Candesartan has been speciﬁ  cally evaluated in patients 
intolerant of ACE-I in two trials: SPICE and CHARM-
Alternative (Bart et al 1999; CHARM-Alternative 2003). The 
SPICE investigators found candesartan was associated with 
hypotension (3% vs 0%, no p-value) and serum creatinine 
elevation of 1.1 mg/dL in 1.1% of patients (vs no change in 
placebo-treated patients, no p-value). Renal insufﬁ  ciency and 
hyperkalemia were similar between the treatment groups (no 
p-value). In CHARM-Alternative, patients who experienced 
ACE-I induced cough rarely experienced a recurrence on 
candesartan (0.3%). However, patients who experienced 
angioedema, hypotension, and renal dysfunction on an ACE-I 
had a 2.6%, 9.1%, and 23.1% chance, respectively, of experi-
encing that same side effect on candesartan. As such, ACE-I 
intolerant patients may tolerate candesartan, but patients who 
experienced hypotension or renal dysfunction on an ACE-I 
should be monitored closely if given candesartan as an al-
ternative agent. Although the CHARM trial demonstrated a 
low recurrence of angioedema on candesartan, conclusions 
regarding the true rate and severity of recurrence cannot be 
made given the limited power of this part of the trial. As such, 
we recommend that patients who experience angioedema on 
an ACE-I should be given a combination of hydralazine and 
nitrate as an alternative rather than an ARB at this time.
The increased rate of cancer-related deaths in the CHARM 
trial has raised concerns. The investigators attribute this to 
chance. Unpublished candesartan data on ﬁ  le at AstraZeneca 
was pooled with the CHARM data to assess comprehensive 
experience, which showed no difference between investi-




Hübner and colleagues (1997) compared the pharmacokinet-
ics of candesartan in healthy geriatric volunteers (average age 
68) with young volunteers (average age 27). The maximum 
concentration (Cmax) was 50%–70% higher in elderly subjects 
after single dose administration of 4–16 mg of candesartan 
compared with young subjects; however, accumulation of 
candesartan did not occur after repeated once daily dosing. 
In addition, the time to reach serum concentration was similar 
between both groups. Area under the curve (AUC) increases 
were also observed, but no data was reported. The half-life 
(t½) was 9–12 h in the elderly volunteers compared with 9 h in 
younger subjects. No baseline or post-treatment information 
was provided regarding blood pressure or heart rate. In 
spite of the pharmacokinetic difference in elderly subjects, 
no dose adjustments are recommended for elderly patients. 
As with other antihypertensive agents in geriatric patients, 
it is reasonable to start candesartan at a low dose and titrate 
according to tolerability and blood pressure goals.
Renal dysfunction
The pharmacokinetics of candesartan cilexetil were studied 
in hypertensive patients with varying levels of renal function. 
The effects of single and multiple daily doses of candesartan 
8mg were evaluated in patients with a creatinine clear-
ance (CrCl) of >60 mL/min/1.73 m
2 (group A), 30–60 mL/
min/1.73 m
2 (group B, moderate renal dysfunction), and 
15–30 mL/min/1.73 m
2 (group C, severe renal dysfunction) 
(Buter et al 1999). Patients with severe impairment displayed 
higher AUC and trough serum concentrations compared with 
normal renal function (p<0.05). The t½ increased with wors-
ening renal status (group A 7.1 hours, group B 10.0 hours, 
and group C 15.7 hours), but no signiﬁ  cant drug accumulation 
occurred. Patients with moderate to severe renal impairment 
experienced a signiﬁ  cantly reduced mean arterial pressure 
versus those with normal renal function (p<0.05; group A 
−7 mmHg, group B −13 mmHg, group C −9 mmHg). 
Candesartan was further evaluated in patients with 
varying degrees of renal function, including those on dialy-
sis (normal CLcr >60 mL/min/1.73 m
2; moderate dysfunc-
tion CLcr 31–60 mL/min/1.73 m
2; severe dysfunction CLcr 
15–30 mL/min/1.73 m
2 with and without hemodialysis 2–4 
days/week) (de Zeeuw, et al 1997). A progressive increase in 
mean Cmax, t1/2, and AUC was observed with worsening renal 
impairment after multiple dosing of candesartan cilexetil 
12 mg/day. The Cmax and AUC values were increased by 60% 
and 110%, respectively, in patients with severe impairment 
(CLcr 15–30 ml/min/1.73 m
2, not requiring dialysis) compared 
with normal renal function; however, trough mean reductions 
in systolic and diastolic blood pressure were similar in both 
groups (no p-value). In hemodialysis patients who received 
8 mg of candesartan, the mean extraction ratio and mean 
recovery of the drug were low: 0.016% and 0.18%, respec-
tively. Higher AUC and Cmax values were observed compared 
with patients with normal renal function; however, no symp-
tomatic hypotension was reported. In a dose escalation study, 
candesartan was assessed in hemodialysis patients (Ottosson Clinical Interventions in Aging 2006:1(4) 364
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et al 2003). Nine patients receiving chronic dialysis were 
titrated up to 16 mg of candesartan cilexetil with stable blood 
pressure; however four patients discontinued treatment due to 
hypotension. Trough plasma concentrations followed linear 
pharmacokinetics with little drug accumulation at the higher 
dosage of 16 mg/day. Although there are no speciﬁ  c recom-
mendations for dosage adjustment in patients with renal 
insufﬁ  ciency, candesartan should be used cautiously with 
close monitoring after initiation and during dose titration. 
Hepatic dysfunction
Two studies showed no signiﬁ  cant differences in pharmacokinetic 
parameters after administration of candesartan cilexetil 12 mg 
(either as single and multiple doses) in patients with mild to mod-
erate hepatic impairment compared with healthy subjects (de 
Zeeuw et al 1997; Hoogkamer et al 1998). However, clinically 
signiﬁ  cant differences were found in another study evaluating a 
single dose of candesartan cilexetil 16 mg in patients with mild 
(Child Pugh A) to moderate (Child Pugh B) hepatic impairment 
versus healthy controls (FDA 2006a). After single 16 mg dose, 
AUC values increased by 145% (p=0.027) and Cmax values 
increased by 73% (p=0.174) in patients with moderate liver 
impairment versus healthy controls. In patients with mild hepatic 
impairment, AUC and Cmax values increased to a lesser degree 
over healthy controls and were not statistically signiﬁ  cant. 
Comparisons of adverse events or different clinical responses 
between patients with varying degrees of hepatic dysfunction 
were not provided in these studies. Given the absence of clinical 
markers to guide use, the pharmacokinetic data suggests that 
for mild hepatic impairment, no dose adjustment is necessary 
upon initiation, but patients with moderate impairment may 
need lower starting doses as a precaution. Investigations of 
candesartan cilexetil in patients with severe hepatic dysfunction 
are needed to ascertain safety in this population. 
Conclusion
In summary, only valsartan and candesartan have prospective, 
randomized, controlled, clinical trial data showing improved 
outcomes in patients with HF. Both agents are approved to be 
used as an alternative to ACE-I. Candesartan is approved to 
be used in combination with an ACE-I, but valsartan is not. 
Both ARBs have been studied in combination with an ACE-I; 
however, in patients already established on and tolerating an 
ACE-I, only candesartan has been shown to further improve 
outcomes. Candesartan did not show statistical beneﬁ  t in patients 
with preserved LV EF; however, the role of RAAS agents for 
isolated diastolic dysfunction needs further study. Other trials 
have looked promising in evaluating candesartan’s effects on 
surrogate endpoints in patients with preserved LV EF (Little 
et al 2004; Kasama et al 2005). 
Patients who cannot tolerate an ACE-I due to cough, 
hypotension, or renal dysfunction should be given a trial on 
candesartan or valsartan. For those on established ACE-I 
therapy, a reasonable approach would be to add candesartan 
in patients who are on goal doses of ACE-I and β-blockers and 
who continue to experience disease progression (ACC–AHA 
2005). Clinicians must be prudent about adding an ARB, as 
not all patients are candidates. Notably, the safety of triple 
therapy (ARB, ACE-I, plus β-blocker) has been questioned 
(Cohn et al 2001); as such, even though this ﬁ  nding was not 
conﬁ  rmed, it is rational to reserve this therapy to patients in 
whom compliance with standard therapy has been reasonably 
conﬁ  rmed, but who still experience disease progression. The 
safety of using ACE-I, ARBs, and aldosterone antagonists 
together is questionable and should be avoided (ACC–AHA 
2005). Also, the data in special populations is limited in num-
bers and by lack of consistent peer review; if candesartan use 
is attempted in these groups, close monitoring of vital signs, 
laboratory values, and symptoms is essential. To summarize, 
candesartan signiﬁ  cantly lowers cardiovascular mortality, 
overall mortality, and HF hospitalizations in patients with 
LV systolic dysfunction. As such, it is an appropriate alterna-
tive to ACE-I intolerant patients or to appropriately selected 
patients on established ACE-I therapy. 
References
Adams KF, Lindenfeld J, Arnold JMO, et al. 2006. Executive Summary: 
HFSA 2006 Comprehensive heart failure practice guideline. J Cardiac 
Failure, 12:10-38.
Aghababian RV. 2002. Acutely decompensated heart failure: opportuni-
ties to improve care and outcomes in the emergency department. Rev 
Cardiovasc Med, 3(suppl 4):S3-9.
[ACC–AHA] American College of Cardiology–American Heart Asso-
ciation. 2005. Guideline update for the diagnosis and management of 
chronic heart failure in the adult. Circulation, 112:1825-52.
[AHA] American Heart Association. 2006. Heart disease and stroke statistics 
– 2006 update. Dallas: AHA.
Bart BA, Ertl G, Held P, et al. 1999. Contemporary management of patients 
with left ventricular systolic dysfunction: Results from the Study of 
Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. 
Eur Heart J, 20:1182-90.
Biollaz J, Brunner HR, Gavras I, et al. 1982. Antihypertensive therapy with 
MK 421: angiotensin II-renin relationships to evaluate efﬁ  cacy of con-
verting enzyme blockade. J Cardiovasc Pharmacol, 4:966-72.
Buter H, Navis GY, Woittiez AJJ, et al. 1999. Pharmacokinetics and pharma-
codynamics of candesartan cilexetil in patients with normal to severely 
impaired renal function. Eur J Clin Pharmacol, 54:953-8.
[CHARM-Added] McMurray JJV, Ostergren J, Swedberg K, et al. 2003. 
Effects of candesartan in patients with chronic heart failure and reduced 
left-ventricular systolic function taking angiotensin-converting-enzyme 
inhibitors. Lancet, 362:767-71.
[CHARM-Alternative] Granger CB, McMurray JJV, Yusuf S, et al. 2003. 
Effects of candesartan in patients with chronic heart failure and reduced 
left-ventricular systolic function intolerant to angiotensin-converting-
enzyme inhibitors. Lancet, 362:772-6.Clinical Interventions in Aging 2006:1(4) 365
Candesartan in heart failure
[CHARM-Overall] Pfeffer MA, Swedberg K, Granger CB, et al. 2003. Ef-
fects of candesartan on mortality and morbidity in patients with chronic 
heart failure. Lancet, 362:759-66.
[CHARM-Preserved] Yusuf S, Pfeffer MA, Swedberg K, et al. 2003. Ef-
fects of candesartan in patients with chronic heart failure and preserved 
left-ventricular ejection fraction. Lancet, 362:777-81.
Cohn JN, Tognoni G; for the Valsartan Heart Failure Study Group. 2001. 
A randomized trial of the angiotensin receptor blocker valsartan in 
chronic heart failure. N Engl J Med, 345;1667-75.
d’Amore A, Black JM, Thomas WG. 2005. The angiotensin II type 2 receptor 
causes constitutive growth of cardiomyocytes and does not antagonize 
angiotensin II type 1 receptor-mediated hypertrophy. Hypertension, 
46:1347-54.
Delgado RM, Willerson JT. 1999. Pathophysiology of heart failure: a look 
at the future. Tex Heart Inst J. 26:28-33.
de Zeeuw D, Remuzzi G, Kirch W. 1997. Pharmacokinetics of candesartan 
cilexetil in patients with renal or hepatic impairment. J Hum Hypertens, 
11(suppl 2):S37-42.
Dostal DE. 2000. The cardiac rennin-angiotensin system: Novel signal-
ing mechanisms related to cardiac growth and function. Regul Pept, 
91:1-11.
Easthope SE, Jarvis B. 2002. Candesartan cilexetil: an update of its use in 
essential hypertension. Drugs, 62:1253-87.
Farrell DM, Wei CC, Tallaj J, et al: 2001. Angiotensin II modulates cat-
echolamine release into interstitial ﬂ  uid of canine myocardium in vivo. 
Am J Physiol Heart Circ Physiol, 281:H813-22.
Flather MD, Yusuf S, Køber L, et al. 2000. Long-term ACE-inhibitor therapy 
in patients with heart failure or left-ventricular dysfunction: a systematic 
overview of data from individual patients. Lancet, 355:1575-81.
Francis GS, Wilson Tang WH, Sonneblick EH. 2004. Pathophysiology of 
heart failure. In: Fuster V, Alexander RW, O’Rourke RA (eds). Hurst’s: 
the heart. 11th ed. New York: McGraw-Hill [online]. Accessed 18 March 
2006. URL: http//www.accessmedicine.com/. 
Garg R, Yusuf F. 1995. Overview of randomized trials of angiotensin-con-
verting enzyme inhibitors on morbidity and mortality in heart failure. 
JAMA, 273:1450-56.
Granger CB, Ertl G, Kuch J, et al. 2000. Randomized trial of candesartan 
cilexetil in the treatment of patients with congestive heart failure and 
a history of intolerance to angiotensin-converting-enzyme inhibitors. 
A Heart J, 139:607-17. 
Granger CB, Swedberg K, Edman I, et al. 2005. Adherence to candesartan 
and placebo and outcomes in chronic heart failure in the CHARM 
programme: double-blind, randomized, controlled clinical trial. Lancet, 
366:2005-11.
[HFSA] Heart Failure Society of America. 2006. 2006 Guideline executive 
summary. J Card Fail, 2-2006(12):10-38.
Hoogkamer JFW, Kleinbloesem CH, Ouwerkerk M, et al. 1998. Pharma-
cokinetics and safety of candesartan cilexetil in subjects with normal 
and impaired liver function. Eur J Clin Pharmacol, 54:341-45.
Hübner R, Högemann AM, Sunzel M, et al. 1997. Pharmacokinetics of 
candesartan after single and repeated doses of candesartan cilexetil 
in young and elderly healthy volunteers. J Hum Hypertens, 11(suppl 
2):S19-25.
Jessup M, Brozena S. 2003. Heart failure. N Engl J Med, 348:2007-18.
Jorde UP, Ennezat PV, Lisker J, et al. 2000. Maximally recommended doses 
of angiotensin-converting enzyme (ACE) inhibitors do not completely 
prevent ACE-mediated formation of angiotensin II in chronic heart 
failure. Circulation, 101:844-6.
Kim s, Iwao H. 2000. Molecular and cellular mechanisms of angiotensin 
II-mediated cardiovascular and renal diseases. Pharmacol Rev, 
52:11-34.
Lévy BI. 2004. Can angiotensin II type 2 receptors have deleterious effects 
in cardiovascular disease? Implications for therapeutic blockade of the 
renin-angiotensin system. Circulation, 109:8-13.
Kasama S, Toyama T, Kumadura H, et al. 2005. Effects of candesartan on 
cardiac sympathetic nerve activity in patients with congestive heart 
failure and preserved left ventricular ejection fraction. J Am Coll 
Cardiol, 45:661-7.
Little WC, Wesley-Farrington DJ, Joyle J, et al. 2004. Effect of candesartan 
and verapamil on exercise tolerance in diastolic dysfunction. J Cardio-
vasc Pharmacol, 43:288-93.
Mitrovic V, Willenbrock R, Miric M, et al. 2003. Acute and 3-month treat-
ment effects of candesartan cilexetil on hemodynamics, neurohormones, 
and clinical symptoms in patients with congestive heart failure. A 
Heart J,145:e14.
McKelvie RS, Yusuf S, Pericad D, et al. 1999. Comparison of candesartan, 
enalapril, and their combination in congestive heart failure: the Ran-
domized Evaluation of Strategies for Left Ventricular Dysfunction 
(RESOLVD) pilot study. Circulation, 100:1056-64.
[MERIT-HF] MERIT-HF Study Group. 1999. Effect of metoprolol CR/XL 
in chronic heart failure: Metoprolol CR/XL randomized intervention 
trial in congestive heart failure (MERIT-HF). Lancet, 353:2001-7.
Mitrovic V, Willenbrock R, Miric M, et al. 2003. Acute and 3-month treat-
ment effects of candesartan cilexetil on hemodynamics, neurohormones, 
and clinical symptoms in patients with congestive heart failure. Am 
Heart J, 145:e14.
Nishikawa K, Naka T, Chatani F, et al. 1997. Candesartan cilexetil: a 
review of its preclinical pharmacology. J Hum Hypertens, 11(suppl 
2):S9-17.
O’Meara E, Solomon S, McMurray J, et al. 2004. Effect of candesartan on 
New York Heart Association functional class: Results of the Candesartan 
in Heart Failure Assessment of Reduction in Mortality and morbidity 
(CHARM) Program. Eur Heart J, 25:1920-6.
Ottosson P, Attman P, Âgren A, et al. 2003. Candesartan cilexetil in haemo-
dialysis patients. Clin Drug Invest, 23:545-50.
Packer M, Bristow MR, Cohn JN, et al; US Carvedilol Heart Failure Study 
Group. 1996. The effect of carvedilol on morbidity and mortality in 
patients with chronic heart failure. N Engl J Med, 334:1349-55.
Pfeffer MA, McMurray JJV, Velazquez EJ, et al; Valsartan in Acute Myo-
cardial Infarction Trial Investigators. 2003. Valsartan, captopril, or both 
in myocardial infarction complicated by heart failure, left ventricular 
dysfunction, or both (VALIANT). N Engl J Med, 349:1893-906. 
Pitt B, Remme W, Zannad F, et al. 2003. Eplerenone, a selective aldosterone 
blocker, in patients with left ventricular dysfunction after myocardial 
infarction. N Engl J Med, 348:1309-21.
Pitt B, Segal R, Martinez FA, et al. 1997. Randomised trial of losartan versus 
captopril in patients over 65 with heart failure (Evaluation of Losartan 
in the Elderly Study: ELITE). Lancet, 349:747-52.
Pitt B, Zannad F, Remme WJ, et al. 1999. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. N Engl 
J Med, 341:709-17.
Rich M. 1997. Epidemiology, pathophysiology, and etiology of congestive 
heart failure in older adults. J Am Geriatr Soc, 45:968-74.
Solomon SD, Wang D, Finn P, et al. 2004. Effect of candesartan on cause-
speciﬁ  c mortality in heart failure patients: The Candesartan in Heart 
Failure Assessment of Reduction in Mortality and morbidity (CHARM) 
Program. Circulation, 110:2180-3.
Riddell JG. 1997. Bioavailability of candesartan is unaffected by food in 
healthy volunteers administered candesartan cilexetil. J Hum Hypertens, 
11(suppl 2):S29-30.
Urata H, Healy B, Stewart RW, et al. 1990. Angiotensin II-forming pathways 
in normal and failing human hearts. Circ Res, 66:883-90.
[FDA] US Food and Drug Administration. 2006a. Candesartan cilexetil, 
Atacand®: clinical pharmacology and biopharmaceutics review [on-
line]. Accessed 18 March 2006. URL: http://www.fda.gov/ohrms/dock-
ets/ac/02/brieﬁ  ng/3877B1_04_FDA-Biopharm.htm.
[FDA] US Food and Drug Administration. 2006b. Candesartan 
cilexetil, Atacand: Label revision, February 22, 2005. Accessed 
18 April 2006. URL: http://www.fda.gov/cder/foi/label/2006/
020838s026lbl.pdf.
van Lier JJ, van Hieningen PN, Sunzel M. 1997. Absorption, metabolism, 
and excretion of 
14C-candesartan and 
14C-candesartan cilexetil in healthy 
volunteers. J Hum Hypertens, 11(suppl 2):S27-8. 
Volpe M, Musumeci B, Paolis PD, et al. 2003. Angiotensin II AT2 receptor 
subtype: an uprising frontier in cardiovascular disease. J Hypertens, 
21:1429-43.Clinical Interventions in Aging 2006:1(4) 366
Ripley et al
Waagstein F, Bristow MR, Swedberg K, et al; for the Metoprolol in Di-
lated Cardiomyopathy (MDC) Trial Study Group. 1993. Beneﬁ  cial 
Effects of Metoprolol in Idiopathic Dilated Cardiomyopathy. Lancet, 
342:1441-6. 
Weber KT. 2001. Aldosterone in congestive heart failure. N Engl J Med, 
345:1689-97.
Widdop RE, Jones ES, Hannan RE, et al. 2003. Angiotensin AT2 receptors: 
cardiovascular hope or hype? Br J Pharmacol, 140:809-24.
Willerson JT. 1995. Other cardiomyopathies. In: Willerson JT, Cohn JN 
(eds). Cardiovascular medicine. New York: Churchill Livingstone, 
888-94.